Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy
-
Published:2017-12
Issue:12
Volume:124
Page:1788-1798
-
ISSN:0161-6420
-
Container-title:Ophthalmology
-
language:en
-
Short-container-title:Ophthalmology
Author:
Francis Jasmine H.,
Habib Larissa A.,
Abramson David H.,
Yannuzzi Lawrence A.,
Heinemann Murk,
Gounder Mrinal M.,
Grisham Rachel N.,
Postow Michael A.,
Shoushtari Alexander N.,
Chi Ping,
Segal Neil H.,
Yaeger Rona,
Ho Alan L.,
Chapman Paul B.,
Catalanotti FedericaORCID
Reference25 articles.
1. MEK and the inhibitors: from bench to bedside;Akinleye;J Hematol Oncol,2013
2. A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study;Fouladi;J Neurooncol,2013
3. Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?;Turner;Expert Opin Pharmacother,2017
4. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial;Dummer;Lancet Oncol,2017
5. Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies;Liu;Retina,2014
Cited by
99 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献